Myelodysplastic Syndromes (MDS)

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Topic(s)

Aplastic Anemia

Pediatric Bone Marrow Failure Diseases

Presenter(s)

Suneet Agarwal, MD, PhD

Suneet Agarwal, MD, PhD from Boston's Children's Hospital provides essential information for families about inherited bone marrow failure disorders in this session from the Patient and Family Conference in Salt Lake City, UT, 2023

Prajwal Dhakal, MD

Institution

University of Iowa Health Care

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Read more about Prajwal Dhakal, MD

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Read more about Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Read more about Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Purpose: In myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Read more about Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Read more about Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

Read more about Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

Approximately 90% of patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management

Read more about Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management

Disease overview: The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN

Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough

Read more about Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough

Therapy-related myelodysplastic syndromes in the genomics era

Read more about Therapy-related myelodysplastic syndromes in the genomics era

Therapy-related myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorder

Subscribe to Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Prajwal Dhakal, MD

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management

Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough

Therapy-related myelodysplastic syndromes in the genomics era

Website Feedback

Patient Helpline